California Biotech Advances Two COVID-19 Products

Source: Streetwise Reports   12/30/2020

Recent news concerning Sorrento Therapeutics’ SARS-CoV-2 virus test and antibodies is discussed in a Dawson James Securities report.

In a Dec. 23 research note, Dawson James Securities analyst Jason Kolbert reported that Sorrento Therapeutics Inc. (SRNE:NASDAQ) submitted to the U.S. Food and Drug Administration an emergency use application for COVI-STIX, the company’s nasal swab antigen test for the presence of the SARS-CoV-2 virus.

Generally, COVI-STIX yields results within 15 minutes but for patients with a high viral load, it can return a positive test in as quickly as two minutes, noted Kolbert.

He relayed, too, that Sorrento received CLIA, or Clinical Laboratory Improvement Amendments, certification which, in part, allows it to test clinical samples.

“Importantly, we see COVID as the beginning, with additional diagnostics in the oncology space now under development,” commented Kolbert.

Also in COVID-19, following encouraging in vitro testing, the California-based biotech is about to launch the first clinical trial of STI-2020, antibodies that neutralize the SARS-CoV-2 virus, the analyst indicated. The purpose is this and subsequent studies is to evaluate the safety, pharmacokinetics and efficacy of a single injection of STI-2020 in two cohorts: healthy volunteers and outpatient COVID-19 patients with mild symptoms.

“The antibody has been engineered for what the company calls ‘ultra-high potency,’ with an expected effective dose in humans to be much lower than current known antibodies being assessed by others in active trials,” Kolbert explained.

This means that if the trials of STI-2020 are positive, Sorrento will need significant capacity to manufacture the product. Accordingly, the company already started the process for production of 100,000 doses, so they should be available in early 2021.

Dawson James has a Buy rating and a $21 per share target price on Sorrento Therapeutics, the stock of which is trading today at about $7.04 per share.

“We have not modeled any revenues on the diagnostics side; as such, it represents upside to our model,” wrote Kolbert.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures for Dawson James Securities, Sorrento Therapeutics, December 23, 2020

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with SRNE in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has NOT received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of November 30, 2020, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm’s investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.